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Synthetic biology: another buzzword?
Life is evolving fast (at least in the ﬁrst world) and the latest
technological gadget becomes outdated even before we have
learnt how to use it. In this respect, science is no exception.
The new buzzword ‘Systems Biology’ entered the vocabulary
of the scientiﬁc community only a few years ago. Now that
every biologist is aware of it and almost everyone seems to be
doing it, an even newer buzzword has entered the scientiﬁc
arena, ‘Synthetic Biology’ (see as an example a sample of
recent reviews on the topic, Benner and Sismour, 2005; Endy,
2005; Andrianantoandro et al, 2006; Heinemann and Panke,
2006).
We are still arguing about the true deﬁnition of Systems
Biology, the more so since it became fashionable for the
funding agencies and therefore any research project should
include itin theproposal,and now weneed todeﬁne Synthetic
Biologyand explainto the non-specialist what the differenceis
between the two. Is Synthetic Biology something really new
or is it simply Biotechnology (another old and outdated
buzzword) in new packaging? What are the achievements so
far, what can we expect from it and are any biosafety dangers
lurking ahead? How is Europe doing in this ﬁeld compared
with other countries? In this brief article we will attempt to
provide some answers to those questions.
What is synthetic biology?
Aconsensus deﬁnition drafted by a group of European experts
deﬁned Synthetic Biology as follows: ‘Synthetic biology is the
engineering of biology: the synthesis of complex, biologically
based (or inspired) systems, which display functions that do
not exist in nature. This engineering perspective may be
applied at all levels of the hierarchy of biological structures—
from individual molecules to whole cells, tissues and organ-
isms. In essence, synthetic biology will enable the design of
‘biological systems’ in a rational and systematic way’
(Synthetic Biology: Applying Engineering to Biology: Report
of a NEST High Level Expert Group). Clearly, an important
aspect of Synthetic Biology that differentiates it from Systems
Biology is the term ‘Engineering’ and ‘Synthesis of novel
functions’. Thus, while Systems Biology attempts to obtain a
quantitative understanding of existing biological systems,
Synthetic Biology is focused on the rational engineering of
these systems. Following this deﬁnition, Synthetic Biology
beneﬁts from the knowledge drawn from Systems Biology
analysis, as well as fromthe conceptual tools developedin this
discipline. Taking it to an extreme, Synthetic Biology is an
engineering discipline and as such needs standard parts that
canbeputtogetherusingbioinformaticandsimulationtoolsto
build circuits that will introduce or modify biological
functions. This would imply that only projects that involve
the use of standardized parts (genes, proteins, circuitsy)
could be considered proper Synthetic Biology projects. In an
ideal world, designing living systems for a practical purpose
should be like redesigning a car to make it more efﬁcient, or
redesigning a computer with a faster processor. One would
have the parts, the right software, the brains and the
knowledge about the targetsystem, and ‘voila `!’ a new bacteria
that produces ethanol from water, CO2 and light has been
created. According to this vision, Synthetic Biology should be
able to rely on a list of standardized parts (amino acids, bases,
proteins, genes, circuits, cells, etcy) whose properties have
been characterized quantitatively and on software modeling
tools that would help putting parts together to create a new
biological function. In this respect, itis encouraging to observe
howfast thenumberof partsand circuitsis growingatthe MIT
‘Registry of Standard Biological Parts’ (http://parts.mit.edu),
encompassing terms that will make any engineer happy
(invertors, noise suppressors etcy).
However, life is not that simple. Although clearly a
repository of well-characterized parts is a great idea, we
should not forget about the daunting complexity of living
systems, especially eukaryotes compared with prokaryotes.
Thus, aside from the challenging task of having a repository of
parts for different organisms (there is no guarantee that a
part that works in Escherichia coli will work in Bacillus
subtilis), we can never rule out the possibility that new
emergentunexpected propertiespop upwhen putting together
parts that have been characterized in isolation or in a different
context. Moreover, if we want to redesign a car, we already
know the speciﬁcations of all its components, how they work
together and how the car will behave under different
conditions. This is obviously not the case for living systems,
where even for the simplest of them we know very little (i.e.,
phagesimpliﬁcationbyChanetal,2005).TomKnight,astrong
advocate of Synthetic Biology, argues that many problems
regarding complexity can be overcome if we keep to key
notions: the principles of hierarchical abstraction, modularity,
standardizationandﬂexibility,anddeﬁneappropriatelevelsof
abstractioninthedescription anddesignofbiologicalsystems.
But the complexity of life continues to surprise us and even
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protein—is becoming more and more eroded, with new
discoveries in epigenetics, splicing, transcript analysis etcy,
increasingly challenging our classical simpliﬁed view of gene
regulation.
Thus,in myopinion, we should considera more relaxeduse
of the term engineering in which the emphasis should be
placed on the design and simulation of the new functions and
properties, rather than on the standardization of parts. This
does not mean that in the long run we should not aim for the
equivalent of a DIN standard for Biological parts, but clearly
we are not there yet. What is important and very much
encouraging is that even without fully understanding how a
living cell operates, we can still redesign it in a meaningful
way. In a similar way that we can now design proteins with
new functions, even if we do not yet fully understand how it
folds and how it performs its function, it is possible to
introduce new functions or modify existing ones in cells
without a complete understanding of the system and without
having a complete list of standardized components. This is
probably possible because living systems are robust and can
tolerate the introduction of foreign networks, which, with
some tinkering, perform the intended function (Andrianan-
toandro et al, 2006).
It is also important to differentiate Synthetic Biology from
Biotechnology. Thus, improving the production of a certain
metabolite by tinkering with some of the components of a
metabolicnetworkwillfallwithintherealmofBiotechnology.On
theotherhand,theintroductionofseveralexogenousenzymesin
an organism to produce a new compound will fall within the
scope of Synthetic Biology. Similarly Systems Biology and
SyntheticBiologyshouldbedifferentiated.Whilebothdisciplines
consider modeling and simulation as important tools, Systems
Biology aims at the quantitative understanding of natural
biological systems, and not at the engineering of new functions,
or properties. Of course Synthetic Biology beneﬁts enormously
from Systems Biology studies, since engineering of a biological
system requires at least some understanding of it. On the other
hand, Systems Biology beneﬁts enormously from engineering
concepts applied to network components (e.g., switches,
ampliﬁers and control elements) and network properties (e.g.,
robustness and modularity), and such studies have provided
invaluable insight into module behavior, while abstracting the
details of molecular interactions (Di Ventura et al, 2006).
Synthetic Biology can operate at every level, from proteins to
organs. Thus, we could consider the 20 amino acids as the
standard parts, protein design algorithms and protein structure
databases as the simulation and bioinformatic tools, and the
resulting newly engineered macromolecule as the new biologi-
cal function. A similar analogy could be performed at higher
levels, with genes and their regulatory transcription factors
being the standard parts, cell-modeling software and databases
the simulation, and bioinformatic tools and the resulting
modiﬁed cell representing the new biological function.
Why has Synthetic Biology become so popular in the last 3–
4 years? Various groups had engineered synthetic genetic
circuits 7 years ago, before the use of the term Synthetic
Biology became so widespread (Becskei and Serrano, 2000;
Elowitz and Leibler, 2000; Gardner and Collins, 2000; Gardner
et al, 2000; Becskei et al, 2001). Since these publications, we
have witnessed an explosion of designed new genetic circuits
in bacteria and eukaryotes, although in the majority of the
cases without a practical application (see next chapter).
Probably, there are three main reasons for this. The ﬁrst one
is the success in designing and engineering small circuits that
could produce complicated behaviors (see examples in Di
Ventura et al, 2006), which suggest that biological systems are
quite robust and easily tolerate the addition of new compo-
nents which could operate in a ‘context-independent’ manner.
The second reason is the incredible developments of DNA
synthesis technologies that have taken place in this period
(Bu ¨gl et al, 2007). These developments have been quickly
adopted by DNA synthesis companies, or are the basis for new
companies. Thus it is affordable now to synthesize your
favoritegeneinsteadofcloningit,andifyouhavethebudget,a
small virus can be assembled simply using the information
stored in a genome database (Tumpey et al, 2005). Although
we have not seen so far widespread use of this technology in
Synthetic Biology, it opens the way for thinking big and for
aiming at the design of very large and complex circuits. This
‘think big’ mood has been very recently boosted by the
demonstration that it is possible to replace the genome of one
organism by another (Lartigue et al, 2007). Finally, the
creation by the MIT of the ‘Registry of Standard Biological
Parts’ (http://parts.mit.edu) has also added to the expecta-
tions and hype in the ﬁeld.
Fundamental versus applied synthetic
biology
Although I will contend that many groups have been doing for
many years what we call now Synthetic Biology (the most
obvious example is Protein Design), it is in the last few years
that we have seen an increasing number of publications
reporting on synthetic circuits of increasing complexity (see
Andrianantoandro et al, 2006 for a recent review). Having said
this, it is important to mention that in the great majority of the
casesthedesignedcircuits havebeen assembledwithoutusing
standard parts and involved some serious tinkering of the
components (Andrianantoandro et al, 2006; Di Ventura et al,
2006). Thus, the discipline is still in its infancy and one can
hope that in the future the concept of standardization, parts
etcy will be applied more widely.
Aside from this and if we except metabolic engineering and
protein design, the majority of the Synthetic Biology advances
realized in recent years have been achieved purely ‘in vitro’
(Isalan et al, 2005), or in microorganisms involving the design
ofsmallgenecircuitsfor‘fun’,thatis,withoutadirectpractical
application, although scientiﬁcally very exciting (see Benner
and Sismour, 2005, #12; Endy, 2005; Andrianantoandro et al,
2006; Heinemann and Panke, 2006 for recent reviews). An
interestingexampleofalargersystemthathasbeenredesigned
is the refactoring of the T7 bacteriophage (Chan et al, 2005).
These studies have offered fundamental insight into biological
processes, like the role and sources of biological noise, the
existence of biological modules with deﬁned properties, the
dynamics of oscillatory behavior, gene transcription and
translation, or cell communication (Andrianantoandro et al,
2006). Thus, in the same way protein design has offered
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and function, Synthetic Biology contributes to the fundamen-
tal understanding of biological processes.
This is not to say that Synthetic Biology has no exciting
future as an applied discipline. A successful example has been
the production of terpenoid compounds in E. coli (Martin et al,
2003) and Saccharomyces cerevisiae (Lindahl et al, 2006; Ro
et al, 2006) that can be used for the synthesis of the anti-
malaria drug In other cases, important steps have been
achieved toward practical applications. For example, an
extensible RNA-based framework has been developed recently
for engineering ligand-controlled gene-regulatory systems,
called ribozyme switches, that exhibits tunable regulation,
designmodularity,and targetspeciﬁcityand could beused, for
example, to regulate cell growth (Win and Smolke, 2007).
Another interesting example is the construction of E. coli
harboring designed plasmids that invade cancer-derived cells
in a density-dependent manner under anaerobic growth
conditions (Anderson et al, 2006, 2007). There are also
promising future applications in the ﬁeld of Bioenergetics,
living vectors for gene therapy, chemical factories, bioreme-
diation etc, but still the discipline needs to deliver and,
importantly, concrete and signiﬁcant applications of Synthetic
Biology should be achieved within the context of a bona ﬁde
engineering discipline involving rational design with the
smallest amount of tinkering.
AsImentionedabove,themajorityoftheworkperformedin
Synthetic Biology has been more in what we will call Basic
Science than in Applied Science (with the exceptions
mentioned). However, this could change rapidly. Nowadays
it is possible to synthesize de novo a small virus, to replace the
genomeofonebacteriumbyanotherandtomakelargechunks
of DNA coding for elaborate genetic circuits. Software tools to
simulate large networks are available, and we can use the
entire panel of omics technologies to analyze the engineered
microorganism. It is quite obvious that all these technologies
will improve further in the incoming years and the day is not
too far when we will be able to synthesize a large eukaryotic
artiﬁcial chromosome. The repository of parts will increase in
complexity, number and reliability of circuits available for
different species. So it is quite conceivable that in 10 years we
will be able to fully redesign or make new cells, bacteria or
viruses. However, it appears that major efforts are still needed
to reach these ambitious objectives. Listening to the talks
given at the Synthetic Biology 3.0 conference in Switzerland
(http://www.syntheticbiology3.ethz.ch), it seems that only a
minority of projects relied on a rigorous engineering approach
as deﬁned by the MIT groups responsible for the parts
repository. Also, the majority of the projects were centered
on developing new experimental and computational tools,
using synthetic biology to understand how organisms work or
to generate minimal cells, but few examples were shown of
fully developed practical applications.
Biosafety, ethical and technology transfer
aspects
Although we are far from it, Synthetic Biology could open the
way to engineer living systems a similar way as we design new
dishwashers, cars, computers or planes. The same way that
engineering has improved our quality of life, but also has
created sophisticated bombers, tanks or the atomic bomb,
SyntheticBiologycouldbeusedforgoodorbad.Wecanexpect
huge beneﬁts as a result, but also—as with any other
important advance in science—there are risks. One obvious
one is related to the accidental release of redesigned
organisms. This concern is in fact similar to the current
Biosafety problems associated with genetically modiﬁed
crops, the use of engineered microorganisms to enhance
production of desired targets etcy, and therefore are well
taken care of by current policies in the matter. The main
concern in Biosecurity arises howeverfrom the possibility that
rogue states or terrorists organization re-engineered micro-
organisms, or living systems with the purpose to harm
Although this seems scary, it is not yet so simple to create a
new pathogenic organism and to release it in an effective way.
Thereareindeed manyunknowns inwhat makesa pathogenic
organism virulent in the environment compared to the
laboratory. Thus, it needs to survive against competing
microorganisms and escape the immune response of the
host. These hurdles and the engineering challenges they
currently represent may however be overcome in some
near future by further advances in science and we need thus
to keep vigilant.
To address all these issues, different bodies, agents and
organizations have started lively discussions to see what will
be the best ways of minimizing the risks associated with
Synthetic Biology (Bhutkar, 2005; Church, 2005; Check, 2006;
Tucker and Zilinskas, 2006) Propositions ranging from self-
regulationofthescientiststogovernment-imposedregulations
have been put forward. One major concrete concern refers to
the purposely design of pathogenic strains taking advantage of
the recent improvements in DNA synthesis (Bu ¨gl et al, 2007).
This has resulted in the proposition of different actions
(discussed on the Internet site of the US synthetic biology
(http://pbd.lbl.gov/sbconf/ and http://syntheticbiology.org/
SB2.0/Biosecurity_and_Biosafety.html) (Bu ¨gl et al, 2007),
mainly centered around the use of efﬁcient software that
could allow DNA synthesis companies to detect orders aiming
at synthesizing possible pathogenic genes or organisms.
However, with the current technologies, it is easy to imagine
that dangerous genes or pathogens could be split into small
inconspicuous oligonucleotides ordered via several dozen
companies dispersed all over the world and that could be
assembled in a third-party laboratory. Thus, Biosecurity in
Synthetic Biology remains an open question. Both in the US
and in the EU several forums for discussion and documents
regarding Biosafety have appeared (http://www.etcgroup.
org/upload/publication/602/01/synbioreportweb.pdf; http://
www.jcvi.org/research/synthetic-genomics-report/; Rathenau
Instituthttp://www.rathenau.nl/;http://openwetware.org/wiki/
Synthetic_Society/Community_Organization_and_Culture).
In the case of the EU, some researchprojects have been funded
to analyze the impact and safety problems of Synthetic
Biology in Europe (SYNBIOSAFE, http://www.synbiosafe.eu;
SYNBIOLOGY, 2005, http://www2.spi.pt/synbiology/). It is
important that European governments and scientiﬁc bodies
think in advance about all the open questions now that the
public yet is not aware of Synthetic Biology. Learning from the
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we should think well in advance the answers we will offer to
society.
Aside fromthe safety problems,wecannot forget the Ethical
issues centered about the complete engineering of new living
forms or the redesign of existing species. Even if these types of
activities do not, in principle, pose an immediate danger in
termsofBiosafetyorBiosecurity,theycanbeeseenasethically
problematic by part of the population, since it will be akin to
playing God. We are not yet there and there is still probably
some time before we can start thinking of the use of synthetic
biology for the improvement of certain features in target
species and logically the possibility of doing it in humans.
Clearly all of these possibilities need to be contemplated and
clearrulesshouldbeestablished,likewehavedoneforhuman
cloning. While designing a new living system for scientiﬁc
purposes is not expected to raise major ethical concerns, the
potential of redesigning human beings clearly needs to be
analyzed from an ethical point of view. Perhaps the ‘playing
God ’ aspect could be more problematic in the US, while in
Europe the redesign of living organisms could be perceived as
a major cause of concern.
Europe versus USA
The immense potential of Synthetic Biology should now
hopefully be obvious to the reader. How well is Europe doing
with respect the world in this emerging ﬁeld? (We recommend
the interested reader to visit the Synbiology website at http://
www2.spi.pt/synbiology/ to get more information on this
topic.)
There have been several serious studies looking at the
number of publications in the ﬁeld per country (Europe/North
America Comparative Assessment available at http://
www2.spi.pt/synbiology). Although we always need to take
those numbers with caution, since European groups often do
not label their ﬁeld of research with the latest buzzword and
therefore might be underrepresented, the numbers speak for
themselves: up to September 2005, 64% of the publications in
the ﬁeld were from US laboratories, versus 24% from Europe,
with the immense majority of those articles that are published
in high-impact journals originating from the US.
This situation could change since the EC has taken an active
role through its Pathﬁnder program, ﬁnancing several projects
in Synthetic Biology and European funding agencies
have included the topic in their new ﬁnancing plans (see
SYNBIOLOGY report).
Regarding European companies working in this area, the
majority are DNA synthesis companies that make large DNA
fragments (for example Febit Synbio or GENEART in Europe),
and small spin-offs from universities and research groups,
the majority of which are, once again, located in the US
(see http://www.etcgroup.org/upload/publication/602/01/
synbioreportweb.pdf). More recently, some companies (i.e.,
Amyris) have appeared in the area of Biofuels, aiming at
redesigning microorganisms for efﬁcient fuel production from
plants. As in the previous case and although there are
European companies working in biofuel production, the
Synthetic Biology companies are mainly starting in the US.
Why are we lagging behind the US? Perhaps it is due to a
general problem in Biology research and the way Europe has
structured its research. In particular, Europe will need to take
more and bolder initiatives in funding and building new
institutes to create the necessary critical mass, and should
raise its ambition for starting novel research areas. Competi-
tive European groups in areas related to Synthetic Biology
deﬁnitely exist, mainly amongst the very top EU institutes,
where the system is more ﬂexible and excellence is actively
pursued. But these few world-class laboratories are usually
small, scattered and in many cases have just entered into the
ﬁeld of Systems Biology and, therefore, do not have the
capacity to fully embark into Synthetic Biology. As in many
otherﬁelds,ifEuropewantstostaycompetitive,wewillneeda
major overhauling of the system, promoting excellence,
ﬂexibility and young investigators with new crazy projects.
In this sense the European Research Council (ERC) initiative
may represent a decisive step forward.
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